Barbarossa G, Renzi A, D'Erasmo L, Gallo A, Grieco E, Rossetti M, Carnovale A, Santilli M, Mandosi E, Coletta P, Pergolini D, Morano S, Maranghi M
Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy.
Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy.
Diabetes Res Clin Pract. 2014 Apr;104(1):e26-8. doi: 10.1016/j.diabres.2013.12.061. Epub 2014 Jan 8.
Low high-density lipoprotein cholesterol (HDL-C) levels are associated with cardiovascular (CV) disease in type 2 diabetes (T2D). Unfortunately available drugs to increase HDL-C have failed to demonstrate a reduction in CV risk. We assessed the effect of improving glycemic control on HDL-C levels. A 6-month intervention resulted in significant improvement in HbA1c but not in HDL-C levels. However, when considering the subgroup of subjects with low levels of HDL-C at baseline, we found a significant and inverse relation between improvement in HbA1c and HDL-C levels.
低高密度脂蛋白胆固醇（HDL-C）水平与2型糖尿病（T2D）患者的心血管（CV）疾病相关。遗憾的是，现有用于升高HDL-C的药物未能证明可降低CV风险。我们评估了改善血糖控制对HDL-C水平的影响。一项为期6个月的干预使糖化血红蛋白（HbA1c）水平显著改善，但HDL-C水平未改善。然而，在考虑基线时HDL-C水平较低的受试者亚组时，我们发现HbA1c的改善与HDL-C水平之间存在显著的负相关关系。
